导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.01% | 1848/4587 |
| 近一周 | -0.06% | 867/5248 |
| 近一月 | 5.22% | 52/5205 |
| 近一季 | 6.10% | 270/5018 |
| 近半年 | 5.39% | 772/4725 |
| 近一年 | 4.05% | 1854/4241 |
| 近两年 | 41.22% | 1776/2862 |
| 近三年 | 50.77% | 525/2171 |
| 成立以来 | 61.33% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-2.93% 2972/4961 |
-8.45% 3883/5312 |
- - |
- - |
| 2025 | 11.01% 2769/4813 |
2.70% 1291/3635 |
12.08% 117/4076 |
-8.95% 4064/4524 |
5.93% 388/4813 |
| 2024 | 41.87% 7/3463 |
10.60% 50/2808 |
7.34% 91/3014 |
13.13% 2233/3129 |
5.64% 581/3463 |
| 2023 | -2.72% 602/2656 |
-2.71% 2042/2280 |
2.13% 162/2385 |
5.02% 104/2515 |
-6.77% 1914/2655 |
| 2022 | -4.81% 109/2207 |
2.22% 68/1919 |
-1.52% 1736/2016 |
-8.55% 208/2113 |
3.40% 700/2208 |
| 2021 | -1.09% 782/1822 |
10.47% 37/1255 |
-2.63% 1221/1330 |
-7.47% 1055/1466 |
-0.62% 1259/1822 |
| 2020 | -0.87% 947/1250 |
-15.00% 975/1028 |
1.78% 985/1067 |
4.54% 951/1164 |
9.60% 629/1184 |
| 2019 | 25.47% 599/1092 |
16.30% 674/754 |
2.42% 84/804 |
-0.95% 626/850 |
6.35% 621/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇添富中证银行ETF VS. 长安沪深300非周期A(740101) |